(NASDAQ: ROIV) Roivant Sciences's forecast annual revenue growth rate of 218.66% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.79%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.21%.
Roivant Sciences's revenue in 2025 is $23,233,000.On average, 12 Wall Street analysts forecast ROIV's revenue for 2026 to be $16,105,083,027, with the lowest ROIV revenue forecast at $6,023,016,973, and the highest ROIV revenue forecast at $33,700,214,017. On average, 12 Wall Street analysts forecast ROIV's revenue for 2027 to be $67,722,065,335, with the lowest ROIV revenue forecast at $6,023,016,973, and the highest ROIV revenue forecast at $171,744,758,365.
In 2028, ROIV is forecast to generate $618,438,192,913 in revenue, with the lowest revenue forecast at $282,221,366,747 and the highest revenue forecast at $1,049,589,238,991.